Abatacept + Glucocorticoid Treatment
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Giant Cell Arteritis
Conditions
Giant Cell Arteritis
Trial Timeline
Jul 15, 2017 → Nov 23, 2021
NCT ID
NCT03192969About Abatacept + Glucocorticoid Treatment
Abatacept + Glucocorticoid Treatment is a phase 3 stage product being developed by Bristol Myers Squibb for Giant Cell Arteritis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03192969. Target conditions include Giant Cell Arteritis.
What happened to similar drugs?
5 of 13 similar drugs in Giant Cell Arteritis were approved
Approved (5) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03192969 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Giant Cell Arteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| prednisone | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| Pexidartinib | Daiichi Sankyo | Phase 2 | 39 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |
| Baricitinib | Eli Lilly | Phase 2 | 35 |
| Upadacitinib + Corticosteroid (CS) | AbbVie | Phase 3 | 40 |
| dovitinib | Novartis | Phase 2 | 35 |
| Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. | Novartis | Phase 3 | 40 |
| Secukinumab 300 mg, s.c. + Prednisolone + Placebo | Novartis | Phase 2 | 35 |
| Secukinumab | Novartis | Phase 1 | 29 |
| Secukinumab 300 mg + Secukinumab 150 mg | Novartis | Phase 3 | 40 |
| Tocilizumab + Placebo | Roche | Phase 3 | 44 |
| Tocilizumab + Prednisone | Roche | Approved | 43 |
| Tocilizumab | Roche | Phase 3 | 40 |
| Tocilizumab | Roche | Phase 1 | 29 |
| Valganciclovir | Roche | Approved | 35 |
| Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate | Roche | Phase 3 | 40 |
| Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs) | Roche | Phase 2 | 35 |
| tocilizumab and IV steroids combination | Roche | Phase 2 | 31 |
| Denosumab | Amgen | Approved | 43 |